[February 6, 2019] —Johnson & Johnson Innovation, the Lung Cancer Initiative (LCI) at Johnson & Johnson, and Janssen Research & Development, LLC today announced that Swedish medical technology company PExA has been selected the awardee of the Carcinogenic Exposure Meter Quickfire Challenge. The Challenge sought innovative, minimally invasive medical device approaches that aim to measure lung damage resulting from exposure to tobacco smoke.
PExA has developed and commercializes a technology that allows researchers to non-invasively collect proximal biomarkers for lung diseases. As the awardee of the Carcinogenic Exposure Meter Quickfire Challenge, PExA will receive $250,000 in grant funding to further advance its technology as well as mentoring from experts at Johnson & Johnson Innovation, the LCI and Janssen.
According to the Center for Disease Control and Prevention (CDC), smoking is the number one risk factor for lung cancer, causing about 80 to 90 percent of lung cancers in the United States.
Preventing tobacco use among youth is critical to ending the world-wide tobacco epidemic. The Carcinogenic Exposure Meter QuickFire Challenge was launched in August 2018 in an effort to help reduce the tobacco epidemic by developing carcinogenic exposure meter technologies that could show smokers the damage they are causing to their bodies through real-time measurement of the effect of carcinogens.
The QuickFire Challenges are managed by Johnson & Johnson Innovation – JLABS, a global network of open innovation ecosystems, enabling and empowering innovators across a broad healthcare spectrum including pharmaceutical, medical device, consumer and health tech sectors to create and accelerate the delivery of possible life-saving, life-enhancing health and wellness solutions to patients around the world.
For more information about the QuickFire Challenge, please visit: https://jlabs.jnjinnovation.com/quickfire-challenges.
About Johnson & Johnson Innovation
Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers; Johnson & Johnson Innovation - JLABS; Johnson & Johnson Innovation – JJDC, Inc.; and our business development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. JLABS provides the laboratories, expertise, education, tools and resources needed to help life science startups thrive, all with no strings attached. A Johnson & Johnson Innovation Center for Device Innovation at the Texas Medical Center (CDI @ TMC) has been established to accelerate the development of medical devices. For more information about Johnson & Johnson Innovation, please visit: www.jnjinnovation.com or follow @JNJinnovation.
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com . Follow us at @JanssenGlobal. Janssen Research & Development, LLC is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Johnson & Johnson Innovation - JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators across a broad healthcare spectrum including pharmaceutical, medical device, consumer and health tech sectors to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS, we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS also produces campaigns to seek out the best science called QuickFire Challenges. For more information, visit www.jlabs.jnjinnovation.com or follow @JLABS.
# # #
 Center for Disease Control and Prevention (CDC): What are the Risks of Lung Cancer? Accessed online: https://www.cdc.gov/cancer/lung/basic_info/risk_factors.htm
 WHO report on the global tobacco epidemic, 2017. Monitoring tobacco use and prevention policies.